Table 2.
Day 0 (5 months old)
|
Day 42 post-treatment
|
Two-way ANOVA (p-value)
|
|||||||
---|---|---|---|---|---|---|---|---|---|
WT | TNF-tg | WT
|
TNF-tg
|
Treatment Placebo vs GC |
Genotype WT vs TNF-tg |
Interaction | |||
Placebo | GC | Placebo | GC | ||||||
MTMR | 1.02±0.08 | 0.85±0.22 | 1.00±0.08 | 0.87±0.07 | 0.87±0.17 | 0.72±0.04 | 0.02* | 0.02* | 0.88 |
| |||||||||
CTPR | 0.99±0.06 | 1.06±0.12 | 1.00±0.03 | 1.05±0.03 | 1.04±0.09 | 1.12±0.02 | 0.02* | 0.06 | 0.67 |
| |||||||||
1660 cm−1/1690 cm−1 Ratio | 0.98±0.11 | 0.99±0.24 | 1.00±0.02 | 1.10±0.06 | 0.99±0.14 | 1.13±0.06 | 0.02* | 0.85 | 0.64 |
The Raman parameters have been normalized by the average value calculated among mice in the WT placebo-treated group. (Normalization values were 3.1, 0.3, and 1.7 for the MTMR, CTPR, and 1660 cm−1/1690 cm−1 intensity ratio, respectively).